On February 24, 2025, Telix Pharmaceuticals Limited filed a Form 6-K announcing the change of its reporting currency to USD. Insights on market impact and compliance included.
Discover Telix Pharmaceuticals Limited's 2024 6-K report, detailing financial performance, governance practices, and regulatory compliance to enhance investor confidence.
Discover Telix Pharmaceuticals' current report highlighting the UK approval of Illuccix, filed on February 13, 2025. Stay updated on key developments and SEC compliance.
Discover Telix Pharmaceuticals Limited's significant announcement on Illucix's European approval in their Form 6-K, filed on Jan 17, 2025. Key milestone for growth!
Discover how Telix Pharmaceuticals exceeded its FY24 revenue guidance with $142M in Q4. Insights on financial performance and investor engagement at the JP Morgan Healthcare Conference.
Discover Telix Pharmaceuticals' latest report on acquiring a Next-Gen Therapeutics Platform, enhancing innovation. Key insights and regulatory compliance detailed within.
Explore Telix Pharmaceuticals' December 2024 Form 6-K report featuring BLA filing for TLX250-CDx and CEO remuneration updates. Key insights for investors and stakeholders.